USANA Health Sciences (NYSE:USNA) Shares Down 2.1% Following Insider Selling

Shares of USANA Health Sciences, Inc. (NYSE:USNA) were down 2.1% on Friday following insider selling activity. The company traded as low as $29.79 and last traded at $29.73. Approximately 10,077 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 100,948 shares. The stock had previously closed at $30.37.

Specifically, insider Joshua Foukas sold 5,732 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total value of $186,519.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Mulham Mulham sold 3,234 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the completion of the sale, the insider now owns 12,775 shares of the company’s stock, valued at approximately $421,319.50. This trade represents a 20.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analysts Set New Price Targets

USNA has been the subject of a number of research reports. Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Finally, DA Davidson reduced their target price on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th.

USANA Health Sciences Trading Down 4.4 %

The firm has a market cap of $548.91 million, a P/E ratio of 10.26, a PEG ratio of 0.93 and a beta of 0.98. The company has a fifty day moving average price of $32.53 and a two-hundred day moving average price of $35.90.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The business had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. As a group, sell-side analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in USNA. KBC Group NV increased its position in shares of USANA Health Sciences by 96.6% during the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after purchasing an additional 519 shares during the last quarter. Royce & Associates LP grew its holdings in USANA Health Sciences by 22.2% in the 3rd quarter. Royce & Associates LP now owns 33,143 shares of the company’s stock valued at $1,257,000 after buying an additional 6,031 shares in the last quarter. Quest Partners LLC acquired a new position in USANA Health Sciences in the 3rd quarter valued at $250,000. Pzena Investment Management LLC grew its holdings in shares of USANA Health Sciences by 7.5% during the 3rd quarter. Pzena Investment Management LLC now owns 1,049,610 shares of the company’s stock worth $39,801,000 after purchasing an additional 72,977 shares in the last quarter. Finally, Pacer Advisors Inc. grew its holdings in shares of USANA Health Sciences by 16.5% during the 3rd quarter. Pacer Advisors Inc. now owns 544,256 shares of the company’s stock worth $20,638,000 after purchasing an additional 76,904 shares in the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.